Cargo Therapeutics to discontinue FIRCE-1 Phase 2 study of Firi-cel
CARGO Therapeutic announced that it has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma whose disease relapsed or was refractory to CD19 ...
CARGO Therapeutics to Discontinue FIRCE-1 Phase 2 Study of Firi-cel; Advances Remaining Programs While Evaluating Strategic Options
CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel)1; Company believes results do not support a competitive benefit-risk profile for patients.CARGO to ...